EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mining and engineering novel staphylococcal lysostaphins as species-specific antibacterial agents

Michał Bukowski iD, Aliaksandr Zhydzetski, Alicja Jankowska, Kinga Chlebicka, Daniel Moreno Zarta, Jakub Malerczyk, Filip Włudyka, Helena Tossavainen, Lina Antenucci iD, Perttu Permi, Karolina Świderska, Marcin Drąg und 1 weitere

Antimicrobial Agents and Chemotherapy · 09.11.2026

DOI: 10.1128/aac.00845-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, online erschienen am 09.11.2026. Verfasst von Michał Bukowski und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Analytical Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Finland, Narodowe Centrum Nauki, Riitta and Jorma J. Takanen Foundation Sr.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antimicrobial resistance (AMR) presents a serious global healthcare challenge, with staphylococci, especially Staphylococcus aureus , being the main cause of deadly infections. Peptidoglycan hydrolases, particularly lysostaphins, are highly promising alternatives to traditional antibiotics, collectively termed enzybiotics, due to their specific lytic action against the bacterial cell wall. To thoroughly explore their therapeutic potential, we performed comprehensive genome mining of 118,127 staphylococcal and 500 closely related mammaliicoccal genomes. Ultimately, we discovered 19 unique lysostaphin sequences, divided into four distinct evolutionary clusters. By characterizing five novel lysostaphins alongside known references, we observed diverse lytic activities and species-specificities. Notably, we identified a novel lysostaphin variant from Staphylococcus simulans , Lys-Ssim, representing a previously unknown evolutionary cluster, which exhibits unmatched substrate promiscuity and an unprecedented lytic activity that extends beyond staphylococci. Additionally, structural modeling and site-directed mutagenesis revealed that peptidoglycan hydrolysis by these M23 metalloproteases depends on highly flexible conformations of the binding cleft. Using these structural insights, we successfully engineered lysostaphins with significantly improved enzyme selectivity for S. aureus while nearly eliminating activity against the skin commensal S. epidermidis . We also demonstrated the potential to engineer lysostaphins active against species other than staphylococci. Our findings show that natural staphylococcal lysostaphins are a rich, highly specialized resource for developing rationally engineered, microbiota-friendly antibacterial agents.

Schlagwörter

Stichwörter der Autor:innen

Staphylococcus aureusantimicrobialsenzybioticslysostaphinspeptidoglycan hydrolasesprotein engineeringstaphylococci

Autor:innen und Institutionen

  • Department of Analytical Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.
  • Doctoral School of Exact and Natural Sciences, Jagiellonian University, Krakow, Poland.
  • Department of Biological and Environmental Science, Nanoscience Center, University of Jyvaskyla, Jyvaskyla, Finland.
  • Department of Chemistry, Nanoscience Center, University of Jyvaskyla, Jyvaskyla, Finland.
  • Institute of Biotechnology, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Faculty of Chemistry, Wroclaw University of Science and Technology, Wroclaw, Poland.

ORCID-Profile: Michał Bukowski, Lina Antenucci, Benedykt Władyka

Förderung

  • Research Council of Finland
  • Narodowe Centrum Nauki
  • Riitta and Jorma J. Takanen Foundation Sr
  • Faculty of Biochemistry, Biophysics and Biotechnology under the Strategic Programme Excellence Initiative at Jagiellonian University in Krakow, Poland

Zitieren

APA

Bukowski, M., Zhydzetski, A., Jankowska, A., Chlebicka, K., Zarta, D. M., Malerczyk, J., Włudyka, F., Tossavainen, H., Antenucci, L., Permi, P., Świderska, K., Drąg, M., & Władyka, B. (2026). Mining and engineering novel staphylococcal lysostaphins as species-specific antibacterial agents. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00845-26

Vancouver

Bukowski M, Zhydzetski A, Jankowska A, Chlebicka K, Zarta DM, Malerczyk J, et al. Mining and engineering novel staphylococcal lysostaphins as species-specific antibacterial agents. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00845-26

BibTeX
@article{Bukowski2026,
  author = {Bukowski, Michał and Zhydzetski, Aliaksandr and Jankowska, Alicja and Chlebicka, Kinga and Zarta, Daniel Moreno and Malerczyk, Jakub and Włudyka, Filip and Tossavainen, Helena and Antenucci, Lina and Permi, Perttu and Świderska, Karolina and Drąg, Marcin and Władyka, Benedykt},
  title = {Mining and engineering novel staphylococcal lysostaphins as species-specific antibacterial agents},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00845-26}
}
Kostenlos starten →